Welcome to CDC Stacks | The cardiac magnetic resonance (CMR) approach to assessing myocardial viability - 33474 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
The cardiac magnetic resonance (CMR) approach to assessing myocardial viability
Filetype[PDF - 2.99 MB]


Details:
  • Personal Authors:
  • Pubmed ID:
    21882082
  • Pubmed Central ID:
    PMC3501385
  • Description:
    Cardiac magnetic resonance (CMR) is a noninvasive imaging method that can determine myocardial anatomy, function, perfusion, and viability in a relative short examination. In terms of viability assessment, CMR can determine viability in a non-contrast enhanced scan using dobutamine stress following protocols comparable to those developed for dobutamine echocardiography. CMR can also determine viability with late gadolinium enhancement (LGE) methods. The gadolinium-based contrast agents used for LGE differentiate viable myocardium from scar on the basis of differences in cell membrane integrity for acute myocardial infarction. In chronic myocardial infarction, the scarred tissue enhances much more than normal myocardium due to increases in extracellular volume. LGE is well validated in pre-clinical and clinical studies that now span from almost a cellular level in animals to human validations in a large international multicenter clinical trial. Beyond infarct size or infarct detection, LGE is a strong predictor of mortality and adverse cardiac events. CMR can also image microvascular obstruction and intracardiac thrombus. When combined with a measure of area at risk like T2-weighted images, CMR can determine infarct size, area at risk, and thus estimate myocardial salvage 1-7 days after acute myocardial infarction. Thus, CMR is a well validated technique that can assess viability by gadolinium-free dobutamine stress testing or late gadolinium enhancement.

  • Document Type:
  • Collection(s):
  • Funding:
    1 Z01 HL004607-08 CE/CE/NCIPC CDC HHS/United States
    Z01 HL004607-10/Intramural NIH HHS/United States
    ZIA HL004607-11/Intramural NIH HHS/United States
No Related Documents.
You May Also Like: